FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3094178839> ?p ?o ?g. }

• W3094178839 endingPage "931" @default.
• W3094178839 startingPage "923" @default.
• W3094178839 abstract "PurposeGuidelines recommend short-course (≤10 fractions) external-beam radiation therapy (EBRT) for bone metastases. Stereotactic body radiation therapy (SBRT) may also improve outcomes; however, routine use is not recommended outside clinical trials. We assessed national radiation therapy trends in complex techniques for bone metastases and associated expenditures.Methods and MaterialsUsing a claims-based Medicare data set covering 84% of beneficiaries, we assessed the relative proportion of all radiation episodes represented by bone metastases. We then evaluated use of short-course and long-course (>10 fractions) EBRT, intensity modulated radiation therapy (IMRT), and SBRT for bone metastases in hospital-affiliated outpatient (OPD) or freestanding (FREE) facilities. We assessed differences using χ2d or Wilcoxon rank sum tests for categorical and continuous variables, respectively. We identified associations with modality, fractionation, and expenditures using multivariable logistic/linear regression.ResultsAmong 467,781 radiation episodes for 17 cancer diagnoses, the overall proportion of episodes dedicated to bone metastases (9.4%) was stable from 2015 to 2017, although treatments were increasing in the hospital-affiliated outpatient setting (P < .005). We identified 40,993 episodes for bone metastases, of which 63% were short-course EBRT, 24% were long-course EBRT, 7% were SBRT, and 6% were IMRT. Techniques more common in the hospital-affiliated outpatient setting included short-course EBRT (OPD, 69%, vs FREE, 56%) and SBRT (OPD, 9%, vs FREE, 5%). Techniques more common among free-standing centers included long-course EBRT (OPD, 19%, vs FREE, 31%) and IMRT (OPD, 4%, vs FREE, 9%). From 2015 to 2017, long-course EBRT decreased by an absolute 8%; short-course EBRT, SBRT, and IMRT increased by 4%, 2.5%, and 1%, respectively. The SBRT/IMRT uptake did not differ by setting (P = .4). Differences in expenditures between SBRT and short-course EBRT decreased by a relative 8% in professional and 12% in technical fees.ConclusionsApproximately 1 in 4 patients received long-course EBRT, with small reductions in use largely replaced by complex treatment modalities. However, expenditures for complex modalities also decreased over time. As alternative payment models take effect, quality metrics are needed to ensure appropriate, effective, and safe delivery of complex technologies. Guidelines recommend short-course (≤10 fractions) external-beam radiation therapy (EBRT) for bone metastases. Stereotactic body radiation therapy (SBRT) may also improve outcomes; however, routine use is not recommended outside clinical trials. We assessed national radiation therapy trends in complex techniques for bone metastases and associated expenditures. Using a claims-based Medicare data set covering 84% of beneficiaries, we assessed the relative proportion of all radiation episodes represented by bone metastases. We then evaluated use of short-course and long-course (>10 fractions) EBRT, intensity modulated radiation therapy (IMRT), and SBRT for bone metastases in hospital-affiliated outpatient (OPD) or freestanding (FREE) facilities. We assessed differences using χ2d or Wilcoxon rank sum tests for categorical and continuous variables, respectively. We identified associations with modality, fractionation, and expenditures using multivariable logistic/linear regression. Among 467,781 radiation episodes for 17 cancer diagnoses, the overall proportion of episodes dedicated to bone metastases (9.4%) was stable from 2015 to 2017, although treatments were increasing in the hospital-affiliated outpatient setting (P < .005). We identified 40,993 episodes for bone metastases, of which 63% were short-course EBRT, 24% were long-course EBRT, 7% were SBRT, and 6% were IMRT. Techniques more common in the hospital-affiliated outpatient setting included short-course EBRT (OPD, 69%, vs FREE, 56%) and SBRT (OPD, 9%, vs FREE, 5%). Techniques more common among free-standing centers included long-course EBRT (OPD, 19%, vs FREE, 31%) and IMRT (OPD, 4%, vs FREE, 9%). From 2015 to 2017, long-course EBRT decreased by an absolute 8%; short-course EBRT, SBRT, and IMRT increased by 4%, 2.5%, and 1%, respectively. The SBRT/IMRT uptake did not differ by setting (P = .4). Differences in expenditures between SBRT and short-course EBRT decreased by a relative 8% in professional and 12% in technical fees. Approximately 1 in 4 patients received long-course EBRT, with small reductions in use largely replaced by complex treatment modalities. However, expenditures for complex modalities also decreased over time. As alternative payment models take effect, quality metrics are needed to ensure appropriate, effective, and safe delivery of complex technologies." @default.
• W3094178839 created "2020-10-29" @default.
• W3094178839 creator A5034787589 @default.
• W3094178839 creator A5041827913 @default.
• W3094178839 creator A5043470257 @default.
• W3094178839 creator A5044340498 @default.
• W3094178839 creator A5056322583 @default.
• W3094178839 creator A5061427633 @default.
• W3094178839 creator A5071575315 @default.
• W3094178839 creator A5079162702 @default.
• W3094178839 date "2021-03-01" @default.
• W3094178839 modified "2023-10-16" @default.
• W3094178839 title "Trends in Radiation Therapy for Bone Metastases, 2015 to 2017: Choosing Wisely in the Era of Complex Radiation" @default.
• W3094178839 cites W1984406296 @default.
• W3094178839 cites W1986649657 @default.
• W3094178839 cites W2018038855 @default.
• W3094178839 cites W2149879397 @default.
• W3094178839 cites W2163957259 @default.
• W3094178839 cites W2319646436 @default.
• W3094178839 cites W2479968209 @default.
• W3094178839 cites W2536769127 @default.
• W3094178839 cites W2610902750 @default.
• W3094178839 cites W2782234272 @default.
• W3094178839 cites W2803766273 @default.
• W3094178839 cites W2806882121 @default.
• W3094178839 cites W2922307780 @default.
• W3094178839 cites W2939770857 @default.
• W3094178839 cites W2942040016 @default.
• W3094178839 cites W2944301866 @default.
• W3094178839 cites W2945592235 @default.
• W3094178839 cites W3013251573 @default.
• W3094178839 cites W3015382304 @default.
• W3094178839 cites W3016039910 @default.
• W3094178839 cites W3032651552 @default.
• W3094178839 cites W3092423171 @default.
• W3094178839 doi "https://doi.org/10.1016/j.ijrobp.2020.11.016" @default.
• W3094178839 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8317587" @default.
• W3094178839 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33188862" @default.
• W3094178839 hasPublicationYear "2021" @default.
• W3094178839 type Work @default.
• W3094178839 sameAs 3094178839 @default.
• W3094178839 citedByCount "9" @default.
• W3094178839 countsByYear W30941788392021 @default.
• W3094178839 countsByYear W30941788392022 @default.
• W3094178839 countsByYear W30941788392023 @default.
• W3094178839 crossrefType "journal-article" @default.
• W3094178839 hasAuthorship W3094178839A5034787589 @default.
• W3094178839 hasAuthorship W3094178839A5041827913 @default.
• W3094178839 hasAuthorship W3094178839A5043470257 @default.
• W3094178839 hasAuthorship W3094178839A5044340498 @default.
• W3094178839 hasAuthorship W3094178839A5056322583 @default.
• W3094178839 hasAuthorship W3094178839A5061427633 @default.
• W3094178839 hasAuthorship W3094178839A5071575315 @default.
• W3094178839 hasAuthorship W3094178839A5079162702 @default.
• W3094178839 hasBestOaLocation W30941788391 @default.
• W3094178839 hasConcept C126838900 @default.
• W3094178839 hasConcept C141071460 @default.
• W3094178839 hasConcept C2989005 @default.
• W3094178839 hasConcept C509974204 @default.
• W3094178839 hasConcept C71924100 @default.
• W3094178839 hasConceptScore W3094178839C126838900 @default.
• W3094178839 hasConceptScore W3094178839C141071460 @default.
• W3094178839 hasConceptScore W3094178839C2989005 @default.
• W3094178839 hasConceptScore W3094178839C509974204 @default.
• W3094178839 hasConceptScore W3094178839C71924100 @default.
• W3094178839 hasFunder F4320314458 @default.
• W3094178839 hasIssue "4" @default.
• W3094178839 hasLocation W30941788391 @default.
• W3094178839 hasLocation W30941788392 @default.
• W3094178839 hasLocation W30941788393 @default.
• W3094178839 hasOpenAccess W3094178839 @default.
• W3094178839 hasPrimaryLocation W30941788391 @default.
• W3094178839 hasRelatedWork W113810927 @default.
• W3094178839 hasRelatedWork W1586374228 @default.
• W3094178839 hasRelatedWork W2003938723 @default.
• W3094178839 hasRelatedWork W2047967234 @default.
• W3094178839 hasRelatedWork W2118496982 @default.
• W3094178839 hasRelatedWork W2364998975 @default.
• W3094178839 hasRelatedWork W2369162477 @default.
• W3094178839 hasRelatedWork W2439875401 @default.
• W3094178839 hasRelatedWork W4238867864 @default.
• W3094178839 hasRelatedWork W2525756941 @default.
• W3094178839 hasVolume "109" @default.
• W3094178839 isParatext "false" @default.
• W3094178839 isRetracted "false" @default.
• W3094178839 magId "3094178839" @default.
• W3094178839 workType "article" @default.